Technical Analysis for CRNX - Crinetics Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 56.07 | 1.63% | 0.90 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Bullish Engulfing | Bullish | 1.63% | |
| Crossed Above 50 DMA | Bullish | 1.63% | |
| Lower Bollinger Band Walk | Weakness | 1.63% | |
| Stochastic Reached Oversold | Weakness | 1.63% | |
| Lower Bollinger Band Touch | Weakness | 1.63% | |
| Oversold Stochastic | Weakness | 1.63% | |
| 50 DMA Resistance | Bearish | 4.41% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Up 2% | about 21 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| Up 1% | about 21 hours ago |
| Fell Below 50 DMA | about 22 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/12/2024
Crinetics Pharmaceuticals, Inc. Description
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Disease Organ Systems Pancreatic Cancer Endocrine System Insulin Stage Pharmaceutical Chemical Entities Neuroendocrine Tumors Acromegaly Neuroendocrine Tumor Endocrine Disease Endocrine Diseases Neuroendocrinology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 62.53 |
| 52 Week Low | 30.5 |
| Average Volume | 760,961 |
| 200-Day Moving Average | 48.82 |
| 50-Day Moving Average | 55.20 |
| 20-Day Moving Average | 57.49 |
| 10-Day Moving Average | 57.75 |
| Average True Range | 2.44 |
| RSI (14) | 47.64 |
| ADX | 14.69 |
| +DI | 22.91 |
| -DI | 24.04 |
| Chandelier Exit (Long, 3 ATRs) | 55.22 |
| Chandelier Exit (Short, 3 ATRs) | 60.15 |
| Upper Bollinger Bands | 61.30 |
| Lower Bollinger Band | 53.68 |
| Percent B (%b) | 0.31 |
| BandWidth | 13.25 |
| MACD Line | 0.14 |
| MACD Signal Line | 0.74 |
| MACD Histogram | -0.5958 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 58.76 | ||||
| Resistance 3 (R3) | 58.58 | 57.50 | 58.31 | ||
| Resistance 2 (R2) | 57.50 | 56.82 | 57.59 | 58.16 | |
| Resistance 1 (R1) | 56.79 | 56.40 | 57.15 | 56.97 | 58.01 |
| Pivot Point | 55.71 | 55.71 | 55.89 | 55.80 | 55.71 |
| Support 1 (S1) | 55.00 | 55.03 | 55.36 | 55.18 | 54.13 |
| Support 2 (S2) | 53.92 | 54.61 | 54.01 | 53.98 | |
| Support 3 (S3) | 53.21 | 53.92 | 53.83 | ||
| Support 4 (S4) | 53.39 |
